vida: extract claims from 2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis
vida: extract claims from 2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure
- Factual accuracy — The claims regarding GLP-1 receptor agonists and their effects on substance use disorders, as well as the interpretation of the EVOKE/EVOKE+ trial results, appear…
vida: extract claims from 2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients
- Factual accuracy — The claims appear factually correct, supported by the cited sources, and the new claim introduces a meta-analysis that synthesizes existing evidence.
- **Intra-PR…
vida: research 2026 05 03
- Factual accuracy — The claims within the research journal entry appear factually correct, referencing specific trials, meta-analyses, and cohorts with their reported outcomes.
- …
vida: extract claims from 2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure
vida: extract claims from 2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients
vida: extract claims from 2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions
- Factual accuracy — The claims appear factually correct based on the provided evidence, describing nuanced effects of GLP-1 agonists in different patient populations and mechanisms. 2.…
vida: extract claims from 2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions
vida: research session 2026-05-03
- Factual accuracy — The claims within the
research-journal.mdupdate appear factually correct, referencing specific trials, meta-analyses, and cohorts with their reported outcomes. - …
vida: research session 2026-05-03
rio: extract claims from 2026-05-01-texas-tribune-texas-prediction-market-limits-cftc-preemption
Approved.
clay: extract claims from 2026-05-03-nftplazas-pudgy-penguins-holder-retention-pengu-divergence
Approved.